{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:55:59Z","timestamp":1792662959011,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["ID2496"],"award-info":[{"award-number":["ID2496"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["ID3519"],"award-info":[{"award-number":["ID3519"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2018\u2014ID. 21963"],"award-info":[{"award-number":["IG 2018\u2014ID. 21963"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cachexia is a debilitating wasting syndrome and highly prevalent comorbidity in cancer patients. It manifests especially with energy and mitochondrial metabolism aberrations that promote tissue wasting. We recently identified nicotinamide adenine dinucleotide (NAD<jats:sup>+<\/jats:sup>) loss to associate with muscle mitochondrial dysfunction in cancer hosts. In this study we confirm that depletion of NAD<jats:sup>+<\/jats:sup> and downregulation of <jats:italic>Nrk2<\/jats:italic>, an NAD<jats:sup>+<\/jats:sup> biosynthetic enzyme, are common features of severe cachexia in different mouse models. Testing NAD<jats:sup>+<\/jats:sup> repletion therapy in cachectic mice reveals that NAD<jats:sup>+<\/jats:sup> precursor, vitamin B3 niacin, efficiently corrects tissue NAD<jats:sup>+<\/jats:sup> levels, improves mitochondrial metabolism and ameliorates cancer- and chemotherapy-induced cachexia. In a clinical setting, we show that muscle <jats:italic>NRK2<\/jats:italic> is downregulated in cancer patients. The low expression of <jats:italic>NRK2<\/jats:italic> correlates with metabolic abnormalities underscoring the significance of NAD<jats:sup>+<\/jats:sup> in the pathophysiology of human cancer cachexia. Overall, our results propose NAD<jats:sup>+<\/jats:sup> metabolism as a therapy target for cachectic cancer patients.<\/jats:p>","DOI":"10.1038\/s41467-023-37595-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T13:04:28Z","timestamp":1680527068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["NAD+ repletion with niacin counteracts cancer cachexia"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6070-9861","authenticated-orcid":false,"given":"Marc","family":"Beltr\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-1260","authenticated-orcid":false,"given":"Noora","family":"P\u00f6ll\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fornelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kialiina","family":"Tonttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam Y.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Corr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-1552","authenticated-orcid":false,"given":"Paolo E.","family":"Porporato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8890","authenticated-orcid":false,"given":"Riikka","family":"Kivel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-0566","authenticated-orcid":false,"given":"Carlo","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-7558","authenticated-orcid":false,"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-2124","authenticated-orcid":false,"given":"Juha J.","family":"Hulmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-9838","authenticated-orcid":false,"given":"Roberta","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-3972","authenticated-orcid":false,"given":"Eija","family":"Pirinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-6027","authenticated-orcid":false,"given":"Fabio","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"37595_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495 (2011).","journal-title":"Lancet Oncol."},{"key":"37595_CR2","doi-asserted-by":"publisher","first-page":"e47258","DOI":"10.15252\/embr.201847258","volume":"20","author":"M Rohm","year":"2019","unstructured":"Rohm, M., Zeigerer, A., Machado, J. & Herzig, S. Energy metabolism in cachexia. EMBO Rep. 20, e47258 (2019).","journal-title":"EMBO Rep."},{"key":"37595_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s, J. M., Busquets, S., Stemmler, B. & L\u00f3pez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754\u2013762 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"37595_CR4","doi-asserted-by":"publisher","first-page":"101046","DOI":"10.1016\/j.molmet.2020.101046","volume":"41","author":"JJ Hulmi","year":"2020","unstructured":"Hulmi, J. J. et al. Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia\u2014the effects of blocking myostatin and activins. Mol. Metab. 41, 101046 (2020).","journal-title":"Mol. Metab."},{"key":"37595_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.aaf2693","volume":"352","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436\u20131443 (2016).","journal-title":"Science"},{"key":"37595_CR6","doi-asserted-by":"publisher","first-page":"361ra139","DOI":"10.1126\/scitranslmed.aaf5504","volume":"8","author":"D Ryu","year":"2016","unstructured":"Ryu, D. et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med. 8, 361ra139 (2016).","journal-title":"Sci. Transl. Med."},{"key":"37595_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/emmm.201403943","volume":"6","author":"NA Khan","year":"2014","unstructured":"Khan, N. A. et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol. Med. 6, 721\u2013731 (2014).","journal-title":"EMBO Mol. Med."},{"key":"37595_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13694-1","volume":"10","author":"E Migliavacca","year":"2019","unstructured":"Migliavacca, E. et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat. Commun. 10, 5808 (2019).","journal-title":"Nat. Commun."},{"key":"37595_CR9","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1530\/JME-18-0085","volume":"61","author":"RS Fletcher","year":"2018","unstructured":"Fletcher, R. S. & Lavery, G. G. The emergence of the nicotinamide riboside kinases in the regulation of NAD+ metabolism. J. Mol. Endocrinol. 61, R107\u2013R121 (2018).","journal-title":"J. Mol. Endocrinol."},{"key":"37595_CR10","doi-asserted-by":"publisher","first-page":"665493","DOI":"10.3389\/fphar.2021.665493","volume":"12","author":"JM Park","year":"2021","unstructured":"Park, J. M., Han, Y. M., Lee, H. J., Park, Y. J. & Hahm, K. B. Nicotinamide Riboside Vitamin B3 Mitigated C26 Adenocarcinoma-Induced Cancer Cachexia. Front. Pharmacol. 12, 665493 (2021).","journal-title":"Front. Pharmacol."},{"key":"37595_CR11","doi-asserted-by":"publisher","first-page":"eadd5163","DOI":"10.1126\/sciadv.add5163","volume":"9","author":"HAK Lapatto","year":"2023","unstructured":"Lapatto, H. A. K. et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci. Adv. 9, eadd5163 (2023).","journal-title":"Sci. Adv."},{"key":"37595_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ajcn\/nqy132","volume":"108","author":"OL Dollerup","year":"2018","unstructured":"Dollerup, O. L. et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 343\u2013353 (2018).","journal-title":"Am. J. Clin. Nutr."},{"key":"37595_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1113\/JP278752","volume":"598","author":"OL Dollerup","year":"2020","unstructured":"Dollerup, O. L. et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J. Physiol. 598, 731\u2013754 (2020).","journal-title":"J. Physiol."},{"key":"37595_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cmet.2020.04.008","volume":"31","author":"E Pirinen","year":"2020","unstructured":"Pirinen, E. et al. Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. Cell Metab. 31, 1078\u20131090.e5 (2020).","journal-title":"Cell Metab."},{"key":"37595_CR15","doi-asserted-by":"publisher","first-page":"6419805","DOI":"10.1155\/2018\/6419805","volume":"2018","author":"E Wyart","year":"2018","unstructured":"Wyart, E. et al. Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting. Oxid. Med. Cell. Longev. 2018, 6419805 (2018).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"37595_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.gastro.2009.11.009","volume":"138","author":"MH Kucherlapati","year":"2010","unstructured":"Kucherlapati, M. H. et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 138, 993\u20131002.e1 (2010).","journal-title":"Gastroenterology"},{"key":"37595_CR17","doi-asserted-by":"publisher","first-page":"eaay9592","DOI":"10.1126\/scitranslmed.aay9592","volume":"13","author":"R Sartori","year":"2021","unstructured":"Sartori, R. et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci. Transl. Med. 13, eaay9592 (2021).","journal-title":"Sci. Transl. Med."},{"key":"37595_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","volume":"5","author":"N Xie","year":"2020","unstructured":"Xie, N. et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 5, 227 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"37595_CR19","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1096\/fj.201801862R","volume":"33","author":"R Ballar\u00f2","year":"2019","unstructured":"Ballar\u00f2, R. et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33, 5482\u20135494 (2019).","journal-title":"FASEB J."},{"key":"37595_CR20","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3390\/cells10113150","volume":"10","author":"M Beltr\u00e0","year":"2021","unstructured":"Beltr\u00e0, M., Pin, F., Ballar\u00f2, R., Costelli, P. & Penna, F. Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration. Cells 10, 3150 (2021).","journal-title":"Cells"},{"key":"37595_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.celrep.2016.12.090","volume":"18","author":"Y Lee","year":"2017","unstructured":"Lee, Y. et al. PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Rep. 18, 918\u2013932 (2017).","journal-title":"Cell Rep."},{"key":"37595_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cmet.2018.03.018","volume":"27","author":"L Liu","year":"2018","unstructured":"Liu, L. et al. Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. Cell Metab. 27, 1067\u20131080.e5 (2018).","journal-title":"Cell Metab."},{"key":"37595_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcsm.12265","volume":"9","author":"JJ Hulmi","year":"2018","unstructured":"Hulmi, J. J. et al. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle 9, 417\u2013432 (2018).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"37595_CR24","doi-asserted-by":"publisher","first-page":"1049653","DOI":"10.3389\/fcell.2022.1049653","volume":"10","author":"T Sonntag","year":"2022","unstructured":"Sonntag, T. et al. Nicotinamide riboside kinases regulate skeletal muscle fiber-type specification and are rate-limiting for metabolic adaptations during regeneration. Front. Cell Dev. Biol. 10, 1049653 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"37595_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.molmet.2017.05.011","volume":"6","author":"RS Fletcher","year":"2017","unstructured":"Fletcher, R. S. et al. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab. 6, 819\u2013832 (2017).","journal-title":"Mol. Metab."},{"key":"37595_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-019-0216-z","volume":"10","author":"CL Doig","year":"2020","unstructured":"Doig, C. L. et al. Induction of the nicotinamide riboside kinase NAD+ salvage pathway in a model of sarcoplasmic reticulum dysfunction. Skelet. Muscle 10, 5 (2020).","journal-title":"Skelet. Muscle"},{"key":"37595_CR27","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","volume":"137","author":"N Diguet","year":"2018","unstructured":"Diguet, N. et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation 137, 2256\u20132273 (2018).","journal-title":"Circulation"},{"key":"37595_CR28","doi-asserted-by":"publisher","first-page":"8484","DOI":"10.1523\/JNEUROSCI.2320-06.2006","volume":"26","author":"Y Sasaki","year":"2006","unstructured":"Sasaki, Y., Araki, T. & Milbrandt, J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J. Neurosci. 26, 8484\u20138491 (2006).","journal-title":"J. Neurosci."},{"key":"37595_CR29","doi-asserted-by":"publisher","first-page":"e98972","DOI":"10.1371\/journal.pone.0098972","volume":"9","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto, T. et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS ONE 9, e98972 (2014).","journal-title":"PLoS ONE"},{"key":"37595_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","volume":"14","author":"J Yoshino","year":"2011","unstructured":"Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528\u2013536 (2011).","journal-title":"Cell Metab."},{"key":"37595_CR31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","volume":"128","author":"D Tong","year":"2021","unstructured":"Tong, D. et al. NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction. Circ. Res. 128, 1629\u20131641 (2021).","journal-title":"Circ. Res."},{"key":"37595_CR32","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","volume":"155","author":"AP Gomes","year":"2013","unstructured":"Gomes, A. P. et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624\u20131638 (2013).","journal-title":"Cell"},{"key":"37595_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"D Narendra","year":"2008","unstructured":"Narendra, D., Tanaka, A., Suen, D.-F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795\u2013803 (2008).","journal-title":"J. Cell Biol."},{"key":"37595_CR34","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","volume":"15","author":"C Cant\u00f3","year":"2012","unstructured":"Cant\u00f3, C. et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838\u2013847 (2012).","journal-title":"Cell Metab."},{"key":"37595_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.redox.2018.04.006","volume":"17","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Nicotinamide riboside attenuates alcohol induced liver injuries via activation of SirT1\/PGC-1\u03b1\/mitochondrial biosynthesis pathway. Redox Biol. 17, 89\u201398 (2018).","journal-title":"Redox Biol."},{"key":"37595_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham, A. et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9, 327\u2013338 (2009).","journal-title":"Cell Metab."},{"key":"37595_CR37","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.26763","volume":"59","author":"P Mukhopadhyay","year":"2014","unstructured":"Mukhopadhyay, P. et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59, 1998\u20132009 (2014).","journal-title":"Hepatology"},{"key":"37595_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/metabo9090180","volume":"9","author":"M Guarino","year":"2019","unstructured":"Guarino, M. & Dufour, J.-F. Nicotinamide and NAFLD: Is There Nothing New Under the Sun? Metabolites 9, 180 (2019).","journal-title":"Metabolites"},{"key":"37595_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1042\/BJ20100791","volume":"433","author":"AA Kendrick","year":"2011","unstructured":"Kendrick, A. A. et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem. J. 433, 505\u2013514 (2011).","journal-title":"Biochem. J."},{"key":"37595_CR40","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1111\/bph.13513","volume":"173","author":"C-C Zhou","year":"2016","unstructured":"Zhou, C.-C. et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br. J. Pharmacol. 173, 2352\u20132368 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"37595_CR41","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jacl.2019.10.006","volume":"13","author":"ML Kashyap","year":"2019","unstructured":"Kashyap, M. L., Ganji, S., Nakra, N. K. & Kamanna, V. S. Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug? J. Clin. Lipidol. 13, 873\u2013879 (2019).","journal-title":"J. Clin. Lipidol."},{"key":"37595_CR42","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1096\/fj.10-168799","volume":"25","author":"CA Goodman","year":"2011","unstructured":"Goodman, C. A. et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 25, 1028\u20131039 (2011).","journal-title":"FASEB J."},{"key":"37595_CR43","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539\u20131547 (2013).","journal-title":"J. Clin. Oncol."},{"key":"37595_CR44","doi-asserted-by":"publisher","first-page":"e104073","DOI":"10.15252\/embj.2019104073","volume":"39","author":"R Acin-Perez","year":"2020","unstructured":"Acin-Perez, R. et al. A novel approach to measure mitochondrial respiration in frozen biological samples. EMBO J. 39, e104073 (2020).","journal-title":"EMBO J."},{"key":"37595_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbabio.2004.09.006","volume":"1659","author":"M Bugiani","year":"2004","unstructured":"Bugiani, M. et al. Clinical and molecular findings in children with complex I deficiency. Biochim. Biophys. Acta 1659, 136\u2013147 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"37595_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.freeradbiomed.2006.04.030","volume":"41","author":"M Collino","year":"2006","unstructured":"Collino, M. et al. Oxidative stress and inflammatory response evoked by transient cerebral ischemia\/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic. Biol. Med. 41, 579\u2013589 (2006).","journal-title":"Free Radic. Biol. Med."},{"key":"37595_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/cancers11030285","volume":"11","author":"R Ballar\u00f2","year":"2019","unstructured":"Ballar\u00f2, R. et al. Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis. Cancers (Basel). 11, 285 (2019).","journal-title":"Cancers (Basel)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37595-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:06:40Z","timestamp":1680530800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37595-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37595"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37595-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"17 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1849"}}